aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above Two Hundred Day Moving Average of $1.55

aTyr Pharma, Inc. (NASDAQ:LIFE) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.55 and traded as high as $1.61. aTyr Pharma shares last traded at $1.60, with a volume of 487,350 shares trading hands.

Analyst Upgrades and Downgrades

LIFE has been the subject of several research analyst reports. Royal Bank of Canada reduced their target price on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $23.67.

aTyr Pharma Trading Up 0.6 %

The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The business’s 50-day moving average is $1.77 and its 200 day moving average is $1.55. The firm has a market capitalization of $109.38 million, a P/E ratio of -1.79 and a beta of 1.27.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.11 million. As a group, analysts anticipate that aTyr Pharma, Inc. will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of aTyr Pharma by 5.1% in the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock worth $13,520,000 after purchasing an additional 413,162 shares during the period. Pale Fire Capital SE acquired a new position in shares of aTyr Pharma in the 3rd quarter valued at approximately $88,000. GSA Capital Partners LLP lifted its holdings in shares of aTyr Pharma by 105.3% during the 1st quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 114,983 shares during the period. Kingswood Wealth Advisors LLC bought a new stake in shares of aTyr Pharma during the 1st quarter worth approximately $117,000. Finally, Granite Bay Wealth Management LLC acquired a new stake in shares of aTyr Pharma during the 4th quarter worth approximately $25,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.